UA115120C2 - Спосіб застосування химерного поліпептиду фактора ix - Google Patents

Спосіб застосування химерного поліпептиду фактора ix

Info

Publication number
UA115120C2
UA115120C2 UAA201301039A UAA201301039A UA115120C2 UA 115120 C2 UA115120 C2 UA 115120C2 UA A201301039 A UAA201301039 A UA A201301039A UA A201301039 A UAA201301039 A UA A201301039A UA 115120 C2 UA115120 C2 UA 115120C2
Authority
UA
Ukraine
Prior art keywords
factor
methods
polypeptides
chimeric
hybrid polypeptides
Prior art date
Application number
UAA201301039A
Other languages
English (en)
Inventor
Гленн Пірс
Саманта Трукс
Роберт Т. Пітерс
Хайянь Джіанг
Original Assignee
Байоджен Хемофіліа Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115120(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байоджен Хемофіліа Інк. filed Critical Байоджен Хемофіліа Інк.
Publication of UA115120C2 publication Critical patent/UA115120C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Винахід стосується способу контролю або запобігання випадків кровотечі у суб'єкта-людини, що цього потребує, який передбачає введення суб'єкту химерного поліпептиду Фактора IX (FIX), що включає FIX і FсRn зв'язувальний партнер (FсRn ВР), у дозі від 50 до 180 МО/кг з інтервалом дозування від 9 до 18 днів, у якому зазначений FсRn ВР включає Fc або альбумін, і у якому концентрація в плазмі крові химерного поліпептиду FIX досягає мінімального рівня щонайменше 1 МО/дл через 6 днів у згаданого пацієнта.
UAA201301039A 2010-07-09 2011-07-11 Спосіб застосування химерного поліпептиду фактора ix UA115120C2 (uk)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36306410P 2010-07-09 2010-07-09
US201061424555P 2010-12-17 2010-12-17
US201161430819P 2011-01-07 2011-01-07
US201161438572P 2011-02-01 2011-02-01
US201161442079P 2011-02-11 2011-02-11
US201161470951P 2011-04-01 2011-04-01
PCT/US2011/043569 WO2012006624A2 (en) 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
UA115120C2 true UA115120C2 (uk) 2017-09-25

Family

ID=45441870

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201301039A UA115120C2 (uk) 2010-07-09 2011-07-11 Спосіб застосування химерного поліпептиду фактора ix
UAA201701696A UA126265C2 (uk) 2010-07-09 2011-07-11 Поліпептид фактора іх і спосіб його застосування

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201701696A UA126265C2 (uk) 2010-07-09 2011-07-11 Поліпептид фактора іх і спосіб його застосування

Country Status (17)

Country Link
US (13) US9670475B2 (uk)
EP (2) EP3552619A1 (uk)
JP (5) JP2013534426A (uk)
KR (5) KR20220097518A (uk)
CN (1) CN103140237A (uk)
AU (5) AU2011274414B2 (uk)
BR (1) BR112013000650A8 (uk)
CA (1) CA2804274A1 (uk)
CL (1) CL2013000058A1 (uk)
EA (2) EA037095B1 (uk)
IL (3) IL223990B (uk)
MX (2) MX356527B (uk)
MY (2) MY192639A (uk)
NZ (1) NZ605348A (uk)
SG (3) SG10201913700SA (uk)
UA (2) UA115120C2 (uk)
WO (1) WO2012006624A2 (uk)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
MY192639A (en) * 2010-07-09 2022-08-29 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
TW201217526A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Chimeric clotting factors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
EA029560B1 (ru) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
CN104487452A (zh) 2012-02-15 2015-04-01 阿穆尼克斯运营公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6317328B2 (ja) 2012-04-11 2018-04-25 ビオベラティブ テラポイティクス インコーポレーテッドＢｉｏｖｅｒａｔｉｖ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． グリコサミノグリカンを検出する方法
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
TWI810729B (zh) * 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
EP2908847B1 (en) * 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
CA2892038C (en) * 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
HUE063051T2 (hu) 2013-02-15 2023-12-28 Bioverativ Therapeutics Inc Optimalizált VIII. faktor gén
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014228938B2 (en) * 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
RU2016129911A (ru) * 2013-12-23 2018-01-30 СиЭсЭл ЛИМИТЕД Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления
MA39779A (fr) 2014-03-24 2017-02-01 Biogen Ma Inc Formulations de facteur ix lyophilisées
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EA201890423A1 (ru) * 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
AU2017250570A1 (en) 2016-04-15 2018-11-15 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
EP3733199A1 (en) 2016-07-08 2020-11-04 CSL Behring Lengnau AG Subcutaneous administration of long-acting factor ix in humans
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
US11185245B2 (en) 2017-06-03 2021-11-30 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure for muscle compartment syndrome
US11045143B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter with connectable hub for monitoring pressure
US10813589B2 (en) 2017-06-03 2020-10-27 Sentinel Medical Technologies, LLC Catheter for monitoring uterine contraction pressure
US10799131B2 (en) 2017-06-03 2020-10-13 Sentinel Medical Technologies, LLC Catheter for monitoring intrauterine pressure to protect the fallopian tubes
US11045128B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter for monitoring intra-abdominal pressure
RU2020103424A (ru) 2017-06-29 2021-07-29 Цсл Беринг Ленгнау Аг Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
AU2019319984A1 (en) 2018-08-09 2021-03-04 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US11672457B2 (en) 2018-11-24 2023-06-13 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
US11779263B2 (en) 2019-02-08 2023-10-10 Sentinel Medical Technologies, Llc. Catheter for monitoring intra-abdominal pressure for assessing preeclampsia
CA3131648A1 (en) 2019-03-19 2020-09-24 CSL Behring Lengnau AG Factor ix variants and uses thereof in therapy
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
WO2021026020A1 (en) 2019-08-08 2021-02-11 Sentinel Medical Technologies, LLC Cable for use with pressure monitoring catheters
US11617543B2 (en) 2019-12-30 2023-04-04 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
WO2023275024A1 (en) * 2021-07-01 2023-01-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
JPH09509054A (ja) 1994-02-01 1997-09-16 アメリカ合衆国 抗体部分および非抗体部分を含む融合タンパク質
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
WO1996022024A1 (en) 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE69841459D1 (en) * 1997-02-14 2010-03-11 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
AU8679298A (en) 1998-07-31 2000-02-21 Wallace E. Carroll Method and apparatus for determining anticoagulant therapy factors
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
IL152448A0 (en) 2000-04-28 2003-05-29 Inflazyme Pharm Ltd 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
BR0212035A (pt) 2001-09-04 2004-08-03 Merck Patent Gmbh Fator ix modificado
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
CN1780637A (zh) * 2003-03-18 2006-05-31 诺和诺德医疗保健公司 因子ⅶ多肽类的含水液体药物组合物
MXPA05010846A (es) 2003-04-09 2006-03-30 Nektar Therapeutics Tratamiento de hemofilia mediante inhalacion de factores de coagulacion.
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7212798B1 (en) * 2003-07-17 2007-05-01 Cisco Technology, Inc. Adaptive AGC in a wireless network receiver
JP2007501812A (ja) 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
CA2545539A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
NZ546733A (en) 2003-12-03 2009-07-31 Novo Nordisk As Glycopegylated factor IX
ATE469216T1 (de) 2004-08-17 2010-06-15 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20090100533A1 (en) 2004-12-21 2009-04-16 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems
US20060162552A1 (en) 2005-01-26 2006-07-27 Mohawk Valley Energy Solutions, Inc. Systems and methods for controlling room air quality
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2626531C (en) 2005-11-01 2011-11-29 Wyeth Sodium chloride solution for drug reconstitution or dilution
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2863222A1 (en) 2006-03-06 2015-04-22 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
SI2004683T1 (sl) 2006-03-24 2016-09-30 Biogen Hemophilia Inc. Pc5 kot encim za obdelavo propeptida faktorja ix
EP2263696A1 (en) * 2006-04-11 2010-12-22 CSL Behring GmbH Method of increasing the in vivo recovery of therapeutic polypeptides
AU2007253264A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor IX analogues having prolonged in vivo half life
DK2256135T3 (da) * 2006-06-14 2019-06-11 Csl Behring Gmbh Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP2084274A2 (en) 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
EP2046371A2 (en) 2006-07-17 2009-04-15 Novo Nordisk Health Care AG Factor viia analogues with increased activity for treating thrombocytopenia
WO2008022151A1 (en) 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
JP2010502208A (ja) * 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
KR20110005862A (ko) 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
EP2282767A4 (en) 2008-04-16 2012-07-11 Bayer Healthcare Llc MODIFICATION OF FACTOR IX ORIENTED SITE
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
US20110183906A1 (en) * 2008-04-24 2011-07-28 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
US20090282865A1 (en) 2008-05-16 2009-11-19 Ortloff Engineers, Ltd. Liquefied Natural Gas and Hydrocarbon Gas Processing
CA2732423A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
BRPI0918988A2 (pt) 2008-09-24 2015-12-01 Stabilitech Ltd métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina.
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
DK2396347T3 (en) 2009-02-11 2017-07-24 Albumedix As ALBUMIN VARIANTS AND CONJUGATES
WO2011030641A1 (ja) 2009-09-08 2011-03-17 コニカミノルタホールディングス株式会社 身体用装具
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2353588B1 (en) 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
CN102939304B (zh) 2010-04-09 2017-04-19 阿尔布麦狄克斯公司 白蛋白衍生物和变体
MY192639A (en) 2010-07-09 2022-08-29 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
EP2705051A1 (en) 2011-05-05 2014-03-12 Novozymes Biopharma DK A/S Albumin variants
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
TWI810729B (zh) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
KR20150118123A (ko) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 약동학적 동물 모델
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
RU2016129911A (ru) 2013-12-23 2018-01-30 СиЭсЭл ЛИМИТЕД Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления

Also Published As

Publication number Publication date
US20160257943A1 (en) 2016-09-08
MX2013000281A (es) 2013-03-22
BR112013000650A2 (pt) 2016-05-31
US20210008178A1 (en) 2021-01-14
US9867873B2 (en) 2018-01-16
JP2013534426A (ja) 2013-09-05
US9629903B2 (en) 2017-04-25
AU2011274414B2 (en) 2016-10-06
US20130171175A1 (en) 2013-07-04
UA126265C2 (uk) 2022-09-14
US10568943B2 (en) 2020-02-25
IL284368A (en) 2021-07-29
JP2019023242A (ja) 2019-02-14
EA028067B1 (ru) 2017-10-31
US20180207244A1 (en) 2018-07-26
CA2804274A1 (en) 2012-01-12
US20130202595A1 (en) 2013-08-08
BR112013000650A8 (pt) 2017-10-17
MY192639A (en) 2022-08-29
AU2017268650B2 (en) 2019-10-10
MY166954A (en) 2018-07-25
KR20190104442A (ko) 2019-09-09
KR20180118808A (ko) 2018-10-31
US20180228879A1 (en) 2018-08-16
US20180228878A1 (en) 2018-08-16
WO2012006624A3 (en) 2012-08-02
KR20140017480A (ko) 2014-02-11
SG10201913700SA (en) 2020-03-30
MX356527B (es) 2018-06-01
KR20230156435A (ko) 2023-11-14
AU2011274414A1 (en) 2013-01-24
AU2016228243B2 (en) 2017-08-31
JP2017036328A (ja) 2017-02-16
IL277432A (en) 2020-11-30
IL277432B (en) 2021-07-29
US9670475B2 (en) 2017-06-06
US20190192640A1 (en) 2019-06-27
AU2016228243A1 (en) 2016-10-06
SG186856A1 (en) 2013-02-28
US20160346365A1 (en) 2016-12-01
US10548954B2 (en) 2020-02-04
CL2013000058A1 (es) 2014-03-28
US10561714B2 (en) 2020-02-18
AU2017268650A1 (en) 2017-12-21
AU2022204643A1 (en) 2022-07-21
US20160166657A1 (en) 2016-06-16
US10898554B1 (en) 2021-01-26
EP2590668A2 (en) 2013-05-15
US20190192641A1 (en) 2019-06-27
EA037095B1 (ru) 2021-02-05
EA201291480A1 (ru) 2013-09-30
US9233145B2 (en) 2016-01-12
CN103140237A (zh) 2013-06-05
US9675676B2 (en) 2017-06-13
EP2590668A4 (en) 2014-04-02
KR20220097518A (ko) 2022-07-07
US9623091B2 (en) 2017-04-18
US20210023185A1 (en) 2021-01-28
EA201790876A1 (ru) 2017-12-29
MX2020009702A (es) 2020-10-07
SG10201505218YA (en) 2015-08-28
AU2020200118B2 (en) 2022-04-07
WO2012006624A2 (en) 2012-01-12
IL223990B (en) 2020-10-29
NZ605348A (en) 2015-01-30
JP2022044828A (ja) 2022-03-17
JP2016034973A (ja) 2016-03-17
EP3552619A1 (en) 2019-10-16
AU2020200118A1 (en) 2020-01-30
US20160243206A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
UA115120C2 (uk) Спосіб застосування химерного поліпептиду фактора ix
MY159135A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
CA140613S (en) Electric toothbrush
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
PH12014501912A1 (en) Cx3cr1-binding polypeptides
MX365403B (es) Peptidos y metodos para usarlos.
HK1200848A1 (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
HK1250743A1 (zh) 表達載體組織、新的生產用細胞產生方法及其在重組產生多肽中的用途
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования
UA59797U (uk) Застосування амкесола як речовини з протикашльовими властивостями
TN2011000545A1 (en) Vinyl indazolyl compounds